Astellas Pharma, Inc.

Astellas Pharma, Inc. saw a significant decline in its stock today, contrasting with the broader market performance of the Japan Nikkei 225. Over the past week and month, Astellas has faced notable downturns, yet it has demonstrated resilience with a substantial increase over the past year. The company maintains a strong financial position.

Astellas Pharma, Inc. faced a decline in stock performance today, contrasting with gains in the Japan Nikkei 225. Despite recent downturns, the company has shown strong annual returns and solid financial health, with a notable market capitalization and a favorable price-to-book ratio, indicating its significance in the pharmaceuticals sector.

Astellas Pharma, Inc. has shown strong performance, with a notable increase on April 15, 2026, and a robust growth of 10.33% over the past month. The company reported a significant annual return of 94.88% and demonstrated solid financial metrics, including a high return on equity and substantial net sales growth.

Astellas Pharma, Inc. has recently undergone a revision in its score, reflecting its strong market performance and financial stability. The company reported a notable growth in net sales and maintains a competitive edge with an attractive valuation. Astellas continues to be a significant player in the Pharmaceuticals & Biotechnology sector.

Astellas Pharma, Inc. has shown strong stock performance, achieving an intraday high and significantly outperforming the Japan Nikkei 225 over the past year. The company reported robust financial metrics, including a 10.4% growth in net sales and a return on capital employed of 19.83%, reinforcing its market position.

Astellas Pharma, Inc. has shown strong stock performance, significantly outperforming the Japan Nikkei 225 over the past year. The company reports a solid return on equity and a high EBIT to interest ratio, alongside notable growth in net sales, reflecting its robust financial health and market position.

Astellas Pharma, Inc. saw a decline in stock price today, contrasting with the broader market trend. Despite recent downturns, the company has shown strong annual performance, with a notable return and healthy financial metrics, including a solid EBIT to Interest ratio and significant growth in net sales.

Astellas Pharma, Inc. saw a decline in its stock price today, contrasting with the broader market's performance. Despite recent fluctuations, the company has shown strong annual returns and maintains solid financial metrics, including a high return on equity and a favorable EBIT to interest ratio.

Astellas Pharma, Inc. saw a significant stock decline today, contrasting with the modest decrease in the Japan Nikkei 225. Over the past year, Astellas has underperformed, with a notable drop compared to the index's gains. Despite challenges, the company shows strong management efficiency metrics.

Astellas Pharma, Inc. faced a significant stock decline today, contrasting with the broader market's performance. Over the past year, the company has seen a notable drop, despite a substantial increase in profits. Astellas maintains a strong EBIT to Interest ratio, reflecting its debt management capabilities.